Drug Trial Radar · NCT06784752
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
May 30, 2025
Primary completion
Dec 8, 2028
Study completion Jan 23, 2034
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 \<10%) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with high disease burden
Conditions
- Somatostatin Receptor Positive (SSTR+)
- Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Interventions
[177Lu]Lu-DOTA-TATERadiation
\[177Lu\]Lu-DOTA-TATE will be administered 4 times during treatment period with frequency of every 8 weeks (Q8W)
Octreotide LARDrug
Octreotide LAR will be administered Q8W when co-administered with \[177Lu\]Lu-DOTA-TATE in the investigational arm followed by Q4W. In the control arm Octreotide LAR will be administered Q4W.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) centrally assessed by Blinded Independent Review Committee (BIRC)Time frame: After observing approximately 88 PFS events as per BIRC assessments, expected after approximately 33 months from study start
Locations
67 sites in 12 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Scottsdale, Arizona · Recruiting
Highlands Oncology Group
Fayetteville, Arkansas · Recruiting
Rocky Mountain Cancer Centers
Denver, Colorado · Recruiting
Hartford Hospital
Hartford, Connecticut · Recruiting
Yale New Haven Hospital
New Haven, Connecticut · Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida · Recruiting
AdventHealth
Orlando, Florida · Recruiting
Piedmont Healthcare
Atlanta, Georgia · Recruiting
Winship Cancer Institute
Atlanta, Georgia · Recruiting
St Elizabeth Healthcare
Edgewood, Kentucky · Recruiting
LSU Medical Center
New Orleans, Louisiana · Recruiting
Henry Ford Hospital
Detroit, Michigan · Recruiting
Mount Sinai Medical Center
New York, New York · Recruiting
Tennessee Oncology
Nashville, Tennessee · Recruiting
TxO Austin Midtown
Austin, Texas · Active not recruiting
Texas Oncology
Dallas, Texas · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Virginia Oncology Associates
Norfolk, Virginia · Recruiting
Blue Ridge Cancer Center
Wytheville, Virginia · Recruiting
Northwest Medical Specialties
Tacoma, Washington · Recruiting
Novartis Investigative Site
Edmonton, Alberta, Canada · Recruiting
Novartis Investigative Site
London, Ontario, Canada · Recruiting
Novartis Investigative Site
Toronto, Ontario, Canada · Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada · Recruiting
Novartis Investigative Site
Beijing, China · Recruiting
Novartis Investigative Site
Beijing, China · Recruiting
Novartis Investigative Site
Beijing, China · Recruiting
Novartis Investigative Site
Shanghai, China · Recruiting
Novartis Investigative Site
Bron, France · Recruiting
Novartis Investigative Site
Clichy, France · Recruiting
Novartis Investigative Site
Montpellier, France · Recruiting
Novartis Investigative Site
Nantes, France · Recruiting
Novartis Investigative Site
Pessac, France · Recruiting
Novartis Investigative Site
Toulouse, France · Recruiting
Novartis Investigative Site
Erlangen, Germany · Recruiting
Novartis Investigative Site
Essen, Germany · Recruiting
Novartis Investigative Site
München, Germany · Recruiting
Novartis Investigative Site
Budapest, Hungary · Recruiting
Novartis Investigative Site
Szeged, Hungary · Recruiting
Novartis Investigative Site
Cona, FE, Italy · Recruiting
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.